Dual-targeted injection poised to rock GLP-1 field in diabetes—and eventually weight loss.
Eli Lilly’s Mounjaro (tirzepatide) is a new way to help adults living with type 2 diabetes keep their levels of glucose under control. It also has the potential to help with obesity, which is a widespread public health issue.
The once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist is taken by injection under the skin at the appropriate dosage, which may be adjusted to meet the blood sugar needs of the individual taking it. It is a single molecule that activates the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Mounjaro comes with an auto-injector pen and a pre-attached hidden needle, making administration user-friendly. It is available in six doses—2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.